Graybug Vision to conduct strategic review; trading halted

Calcimedica

28/06/2022 12:37

** Eye disease-focused drug developer Graybug Vision Inc
 GRAY.O  says it will conduct a strategic review
    ** GRAY will explore options including potential
acquisition, company sale, merger, divestitures, private
placement of equity securities, or other strategic transactions
 urn:newsml:reuters.com:*:nGNX5ypHWP
    ** Share trading halted before the announcement
    ** Co's cash, cash equivalents and short-term investments
total $55.3 mln
    ** GRAY says it has retained Piper Sandler as a financial
adviser for the review
    ** Stock down 54.8% this year, as of Monday's close

 (Reporting by Ruhi Soni in Bengaluru;)
 ((Ruhi.Soni@thomsonreuters.com
Twitter: https://twitter.com/ruhithere))